Pharmacogenetics and antiplatelet drugs;Pharmacogénétique et médicaments antiplaquettaires

Revue de Medecine Interne

Volumn 26, Issue 9, 2005, Pages 725-732

  Fontana, P ^a   Reny, J L ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Centre Hospitalier Beziers   (France)

Author keywords

Antiplatelet drugs; Genetics; Platelets; Polymorphisms; Receptor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN IIIA; ORBOFIBAN; PURINE P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TICLOPIDINE;

ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; PHARMACOGENETICS; REVIEW; THROMBOCYTE AGGREGATION;

EID: 24344505066     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2005.02.006     Document Type: Short Survey

References (67)

1. F.J. Gonzalez, R.C. Skoda, S. Kimura, M. Umeno, U.M. Zanger, and D.W. Nebert Characterization of the common genetic defect in humans deficient in debrisoquine metabolism Nature 331 1988 442 446
2. W.E. Evans, and H.L. McLeod Pharmacogenomics - drug disposition, drug targets, and side effects N. Engl. J. Med. 348 2003 538 549
3. R. Weinshilboum Inheritance and drug response N. Engl. J. Med. 348 2003 529 537
4. G.P. Aithal, C.P. Day, P.J. Kesteven, and A.K. Daly Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 1999 717 719
5. J. van der Weide, L.S. Steijns, M.J. van Weelden, and K. de Haan The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement Pharmacogenet. 11 2001 287 291
6. J.A. Johnson, and J.J. Lima Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges Pharmacogenet. 13 2003 525 534
7. F.D. Martinez, P.E. Graves, M. Baldini, S. Solomon, and R. Erickson Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing J. Clin. Invest. 100 1997 3184 3188
8. M. Cattaneo Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance Arterioscler. Thromb. Vasc. Biol. 24 2004 1980 1987
9. C. Patrono, B. Coller, G.A. FitzGerald, J. Hirsh, and G. Roth Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 3 Suppl 2004 234S 264S
10. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
11. A. Angelillo-Scherrer, P. de Frutos, C. Aparicio, E. Melis, P. Savi, and F. Lupu Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis Nat. Med. 7 2001 215 221
12. P. Andre, K.S. Prasad, C.V. Denis, M. He, J.M. Papalia, and R.O. Hynes CD40L stabilizes arterial thrombi by a beta3 integrin - dependent mechanism Nat. Med. 8 2002 247 252
13. N. Prevost, D. Woulfe, T. Tanaka, and L.F. Brass Interactions between Ephkinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred Proc. Natl. Acad. Sci. USA 99 2002 9219 9224
14. C.J. O'Donnell, M.G. Larson, D. Feng, P.A. Sutherland, K. Lindpaintner, and R.H. Myers Genetic and environmental contributions to platelet aggregation: the Framingham heart study Circulation 103 2001 3051 3056
15. G. Ciabattoni, S. Ujang, P. Sritara, F. Andreotti, G. Davies, and B.M. Simonetti Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty J. Am. Coll. Cardiol. 21 1993 1377 1381
16. Antithrombotic Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration BMJ 308 1994 81 106
17. J.W. Eikelboom, J. Hirsh, J.I. Weitz, M. Johnston, Q. Yi, and S. Yusuf Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 2002 1650 1655
18. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, J. White, and E.J. Topol A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J. Am. Coll. Cardiol. 41 2003 961 965
19. M.K. Halushka, and P.V. Halushka Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 105 2002 1620 1622
20. A. Di Castelnuovo, G. de Gaetano, M.B. Donati, and L. Iacoviello Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis Thromb. Haemost. 85 2001 626 633
21. P.J. Newman, R.S. Derbes, and R.H. Aster The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing J. Clin. Invest. 83 1989 1778 1781
22. M. Crook Platelet prothrombinase in health and disease Blood Coagul. Fibrinolysis 1 1990 167 174
23. R. Kumar, S. Beguin, and H.C. Hemker The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity Thromb. Haemost. 74 1995 962 968
24. A. Szczeklik, A. Undas, M. Sanak, M. Frolow, and W. Wegrzyn Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa Br. J. Haematol. 110 2000 965 967
25. A. Undas, K. Brummel, J. Musial, K.G. Mann, and A. Szczeklik Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury Circulation 104 2001 2666 2672
26. G.E. Cooke, P.F. Bray, J.D. Hamlington, D.M. Pham, and P.J. Goldschmidt-Clermont PlA2 polymorphism and efficacy of aspirin Lancet 351 1998 1253
27. G. Andrioli, P. Minuz, P. Solero, S. Pincelli, R. Ortolani, and S. Lussignoli Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa) Br. J. Haematol. 110 2000 911 918
28. C. Patrono Aspirin resistance: definition, mechanisms and clinical read-outs J. Thromb. Haemost. 1 2003 1710 1713
29. R. Gonzalez-Conejero, J. Rivera, J. Corral, C. Acuna, J.A. Guerrero, and V. Vicente Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 36 2005 276 280
30. A.A. Weber, K.C. Zimmermann, J. Meyer-Kirchrath, and K. Schror Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance Lancet 353 1999 900
31. A. Papafili, M.R. Hill, D.J. Brull, R.J. McAnulty, R.P. Marshall, and S.E. Humphries Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response Arterioscler. Thromb. Vasc. Biol. 22 2002 1631 1636
32. T. Kawasaki, Y. Ozeki, T. Igawa, and J. Kambayashi Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin Stroke 31 2000 591 595
33. L. Macchi, L. Christiaens, S. Brabant, N. Sorel, J. Allal, and G. Mauco Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate Thromb. Res. 107 2002 45 49
34. C. Gachet ADP receptors of platelets and their inhibition Thromb. Haemost. 86 2001 222 232
35. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee Lancet 348 1996 1329 1339
36. P. Fontana, A. Dupont, S. Gandrille, C. Bachelot-Loza, J.L. Reny, and M. Aiach Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects Circulation 108 2003 989 995
37. S.L. Hetherington, R.K. Singh, D. Lodwick, J.R. Thompson, A.H. Goodall, and N.J. Samani Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP Arterioscler. Thromb. Vasc. Biol. 25 2005 252 257
38. P. Fontana, P. Gaussem, M. Aiach, J.N. Fiessinger, J. Emmerich, and J.L. Reny P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study Circulation 108 2003 2971 2973
39. T.A. Clarke, and L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab. Dispos. 31 2003 53 59
40. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
41. I. Muller, F. Besta, C. Schulz, S. Massberg, A. Schonig, and M. Gawaz Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement Thromb. Haemost. 89 2003 783 787
42. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Bienart, and I. Goldenberg Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
43. S.D. Wiviott, and E.M. Antman Clopidogrel resistance: a new chapter in a fast-moving story Circulation 109 2004 3064 3067
44. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Barrera Ramirez, M. Sabate, and C. Fernandez Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J. Invasive Cardiol. 16 2004 169 174
45. W.C. Lau, L.A. Waskell, P.B. Watkins, C.J. Neer, K. Horowitz, and A.S. Hopp Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction Circulation 107 2003 32 37
46. J. Saw, S.R. Steinhubl, P.B. Berger, D.J. Kereiakes, V.L. Serebruany, and D. Brennan Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial Circulation 108 2003 921 924
47. W.C. Lau, P.A. Gurbel, P.B. Watkins, C.J. Neer, A.S. Hopp, and D.G. Carville Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 2004 166 171
48. D.A. Hesselink, R.H. van Schaik, I.P. van der Heiden, M. van der Werf, P.J. Gregoor, and J. Lindemans Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin. Pharmacol. Ther. 74 2003 245 254
49. R.F. Storey, R.G. Wilcox, and S. Heptinstall Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease Platelets 13 2002 407 413
50. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, M. Sabate, and C. Fernandez PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation Blood Coagul. Fibrinolysis 15 2004 89 93
51. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, J. Escaned, and R. Moreno 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment Blood Coagul. Fibrinolysis 15 2004 427 433
52. D.F. Kong, R.M. Califf, D.P. Miller, D.J. Moliterno, H.D. White, and R.A. Harrington Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease Circ. 98 1998 2829 2835
53. R. Curtin, and D.J. Fitzgerald A cold start for oral glycoprotein IIb/IIIa antagonists Eur. Heart J. 21 2000 1992 1994
54. R. Curtin, and D.J. Fitzgerald Pharmacogenetics of antiplatelet drugs Sci.WorldJournal 2 2002 791 800
55. G.L. Wheeler, G.A. Braden, P.F. Bray, S.J. Marciniak, M.A. Mascelli, and D.C. Sane Reduced inhibition by abciximab in platelets with the PlA2 polymorphism Am. Heart J. 143 2002 76 82
56. M. Rozalski, and C. Watala Antagonists of platelet fibrinogen receptor are less effective in carriers of Pl(A2) polymorphism of beta(3) integrin Eur. J. Pharmacol. 454 2002 1 8
57. F.F. O'Connor, D.C. Shields, A. Fitzgerald, C.P. Cannon, E. Braunwald, and D.J. Fitzgerald Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes Blood 98 2001 3256 3260
58. M.J. Quinn, E.F. Plow, and E.J. Topol Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 106 2002 379 385
59. H.C. Diener, L. Cunha, C. Forbes, J. Sivenius, P. Smets, and A. Lowenthal European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke J. Neurol. Sci. 143 1996 1 13
60. T.D. Bjornsson, and C. Mahony Clinical pharmacokinetics of dipyridamole Thromb. Res. Suppl. 4 1983 93 104
61. M.K. Halushka, L.P. Walker, and P.V. Halushka Genetic variation in cyclooxygenase 1: effects on response to aspirin Clin. Pharmacol. Ther. 73 2003 122 130
62. D. Lasne, M. Krenn, V. Pingault, E. Arnaud, J.N. Fiessinger, and M. Aiach Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism Br. J. Haematol. 99 1997 801 807
63. D. Feng, K. Lindpaintner, M.G. Larson, V.S. Rao, C.J. O'Donnell, and I. Lipinska Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study Arterioscler. Thromb. Vasc. Biol. 19 1999 1142 1147
64. J.S. Bennett, F. Catella-Lawson, A.R. Rut, G. Vilaire, W. Qi, and S.C. Kapoor Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets Blood 97 2001 3093 3099
65. A.D. Michelson, M.I. Furman, P. Goldschmidt-Clermont, M.A. Mascelli, C. Hendrix, and L. Coleman Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists Circulation 101 2000 1013 1018
66. Y. Cadroy, K.S. Sakariassen, J.P. Charlet, C. Thalamas, B. Boneu, and P. Sie Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men Blood 98 2001 3159 3161
67. A. Dupont, P. Fontana, C. Bachelot-Loza, J.L. Reny, I. Bieche, and F. Desvard An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN Blood 101 2003 1833 1840